- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07634952
Mitigation of Health Effects in Outdoor Workers by Reducing Exposure to Heat and Air Pollution (ISMED-CLIM OW)
Innovative Solutions Across the MEDiterranean for Mitigation of Climate Change-related heaLth rIsks in Outdoor Workers
The goal of this clinical trial is to assess the effectiveness of an intervention (combination of behavioural recommendations and technical measures) in reducing personal exposure to heat and air pollution and related health effects in outdoor workers.
The main questions it aims to answer are:
- Does the intervention (combination of behavioral recommendations for heat mitigation) reduce personal ambient temperature exposure, measured using a wearable device (iButton)?
- Does the intervention (combination of behavioral recommendations for air pollution mitigation and use of indoor air cleaners) reduce indoor exposure to air pollution, measured using indoor air quality sensors (Purple Air)?
- Does the intervention (combination of behavioral recommendations for heat mitigation) reduce physiological strain experienced by individuals working in hot environments, measured using the Heat Strain Score Index?
Researchers will compare measurements between outdoor workers carrying out their activities in the absence of intervention (control group), those carrying out their activities with behavioural recommendations (recommendation intervention group) and those carrying out their activities with both behavioural recommendations for heat mitigation and continuous use of indoor air cleaners in their house (heat and air pollution mitigation intervention group) to see if changes in temperature exposure and physiological strain are different between intervention groups.
Participants will:
- Wear the wearable devise for continuous personal ambient temperature monitoring (ibutton) daily for a period of three months
- Have their core temperature measured using an eCelsius medical capsule in three repeated assessments
- Complete the Heat Strain Score Index questionnaire in three repeated assessments
- Provide samples of urine, blood, saliva and hair for measurement of various biomarkers in three repeated assessments
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Panayiotis Yiallouros, Professor
- Phone Number: +35722895212
- Email: yiallouros.panayiotis@ucy.ac.cy
Study Contact Backup
- Name: Panayiotis Kouis, PhD
- Phone Number: +35722895243
- Email: kouis.panayiotis@ucy.ac.cy
Study Locations
-
-
-
Trikala, Greece
- Recruiting
- University of Thessaly
-
Contact:
- Andreas Flouris, Professor
- Phone Number: +30 24310 47072
- Email: aflouris@uth.gr
-
-
-
-
-
León, Spain
- Recruiting
- University of Léon
-
Contact:
- Belén Carballo-Leyenda, Professor
- Phone Number: +34 987 293 023
- Email: abcarl@unileon.es
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18-65 years old
- Municipality outdoor workers
- Regularly working outdoors for al least 6 hours per day
- Living in León (Spain) or Trikala (Greece)
- Clinically healthy
- No history of diabetes mellitus type 2 (DM2)
- No history of arterial hypertension
Exclusion Criteria:
- Currently smoking
- Presence of any smoking residents in the household
- Not residing at the household for at least 5 days a week
- Planning to move from the current home within the next two months
- No access to Wi-Fi or 4G/5G mobile phone
- Severe chronic conditions (congestive heart failure, ischemic heart disease, significant valvular heart disease, DM2, inflammatory diseases, renal failure, or active cancer)
- Drugs abuse
- Alcohol abuse
- Psychiatric disorders
- Severe mental disability that interferes with answering questions or following instructions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control group
Subjects in this arm will receive no alerts for high temperatures nor recommendations for mitigation of heat-related health effects.
|
|
|
Experimental: Heat intervention - Personal Alerts and Specific Recommendations
Subjects in this group will receive timely personal alerts for high temperatures and specific recommendations to reduce exposure to heat and mitigation of heat-related health effects in written and animated format through mobile phones, mobile applications and online tools.
|
The participants in this group of intervention will receive timely personal alerts for high temperatures and specific recommendations to reduce exposure to heat by changing patterns of time spent and physical activity performed outdoors, regulating indoor temperature using fans and/or air conditioning devices, as well as recommendations for mitigation of heat-related health effects (hydration, body cooling) in written and animated format, through mobile phones, web application and online tools to be developed by the project research team
Other Names:
|
|
Experimental: Heat and air pollution intervention - Group Alerts, Recommendations and Air Cleaners
Subjects in this group will receive alerts and recommendations as in group "Heat intervention" and in addition, continuously use of air cleaners with HEPA filter for removing PM from indoor air in their residences and workplaces to provide evidence for health benefits.
|
The participants in this intervention group will receive alerts and recommendations as in group "Heat intervention" and, in addition, continuously use air cleaners with HEPA filters for removing PM from indoor air in their residences and workplaces.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heat Strain Score Index
Time Frame: The HSSI will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
The Heat Strain Score Index (HSSI) is a questionnaire-based assessment tool used to assess the risk of heat strain on individuals exposed to hot environments, using a questionnaire.
It integrates multiple factors, such as environmental conditions, work intensity, clothing, and physiological responses, to estimate the likelihood of heat stress affecting a person.
|
The HSSI will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heart Rate
Time Frame: Heart Rate will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Heart rate will be measured using ECG.
|
Heart Rate will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
The personal ambient temperature profile of all participants
Time Frame: Daily measurements - for the whole duration of follow-up (2 months)
|
Personal exposures of participants will be monitored continuously during the two observation months with wearable sensors to be always worn and assess personal exposure to ambient (indoor and outdoor) temperature (iButton).
|
Daily measurements - for the whole duration of follow-up (2 months)
|
|
Serum Urea Levels
Time Frame: Serum levels of urea will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum levels of urea (mg/dL), as a marker of renal function, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum levels of urea will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Serum Creatinine Levels
Time Frame: Serum levels of creatinine will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum levels of creatinine (mg/dL), as a marker of renal function, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum levels of creatinine will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Serum Sodium levels
Time Frame: Serum levels of sodium will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum levels of sodium (mmol/L), as a marker of hydration, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum levels of sodium will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Serum Osmolality
Time Frame: Serum osmolality will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum osmolality (mOsm/kg), as a marker of hydration, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum osmolality will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Urine Creatinine Levels
Time Frame: Urine levels of creatinine will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Urine levels of creatinine (mg/dL), as a marker of renal function, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Urine levels of creatinine will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Urine Sodium levels
Time Frame: Urine levels of sodium will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Urine levels of sodium (mmol/L), as a marker of hydration, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Urine levels of sodium will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Urine Potassium levels
Time Frame: Urine levels of potassium will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Urine levels of potassium (mmol/L), as a marker of hydration, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Urine levels of potassium will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Urine Osmolality
Time Frame: Urine osmolality will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Urine osmolality (mOsm/kg), as a marker of hydration, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Urine osmolality will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Hair cortisol levels
Time Frame: Hair cortisol levels will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Hair cortisol levels (pg/mg), as a marker of stress, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Hair cortisol levels will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Saliva alpha-amylase levels
Time Frame: Saliva levels of alpha-amylase will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Saliva levels of alpha-amylase (U/mL), as a marker of stress, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Saliva levels of alpha-amylase will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: The PSQI will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a one-month time interval.
The PSQI is commonly used in both clinical and research settings to evaluate various aspects of sleep.
It is a valuable tool for assessing sleep quality as it captures multiple dimensions of sleep, including both subjective experiences and objective parameters.
Higher scores indicate poorer sleep quality, with a score greater than 5 suggesting significant sleep difficulties.
|
The PSQI will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Sleep-Wake self-reported evaluation
Time Frame: The sleep-wake self-reported evaluation will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
The sleep-wake self-reported evaluation will be carried out using a predefined sleep diary which will be completed by the participant on the morning after he/she wakes up.
Each assessment of sleep-wake self-reported evaluation will be carried out for a whole week.
|
The sleep-wake self-reported evaluation will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Hamilton Anxiety Rating Scale
Time Frame: The Hamilton Anxiety Rating Scale will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
The Hamilton Anxiety Rating Scale will be carried out to assess the severity of a person's anxiety.
The Hamilton Anxiety Rating Scale ranges from 0 to 56, where higher scores indicate greater anxiety severity.
The scoring is divided into severity tiers: <17 (mild), 18-24 (mild to moderate), and 25-56 (moderate to severe).
The scale consists of 14 items, each rated from 0 to 4 points.
It evaluates both psychic anxiety (e.g., tension, fears, mood) and somatic anxiety (physical complaints).
|
The Hamilton Anxiety Rating Scale will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Systolic/Diastolic Blood Pressure
Time Frame: Systolic/Diastolic blood pressure will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Measurements of Systolic/Diastolic Blood Pressure will be recorded.
|
Systolic/Diastolic blood pressure will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Heart Rate Variability
Time Frame: The heart rate variability will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Heart rate variability will be measured using ECG.
|
The heart rate variability will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Serum C-reactive Protein Levels
Time Frame: Serum levels of C-reactive protein will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum levels of C-reactive protein (mg/L), as a marker of systemic inflammation, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum levels of C-reactive protein will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Serum Potassium Levels
Time Frame: Serum levels of potassium will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum levels of potassium (mmol/L), as a marker of hydration, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum levels of potassium will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Wet-bulb globe temperature (WGBT)
Time Frame: Daily measurements - for the whole duration of follow-up (2 months).
|
Wet-bulb globe temperature, will be assessed as a thermal stress indicator.
|
Daily measurements - for the whole duration of follow-up (2 months).
|
|
Humidity
Time Frame: Daily measurements - for the whole duration of follow-up (2 months).
|
Humidity will be measured using iButton.
|
Daily measurements - for the whole duration of follow-up (2 months).
|
|
Indoor concentration levels of Particulate Matter 2.5 (PM 2.5) at residence
Time Frame: Daily measurements - for the whole duration of follow-up (2 months).
|
Indoor concentration levels of PM2.5 (micrograms per cubic meter of air) at participants' residences will be measured continuously indoors using commercial lightweight sensors (Alpha sense).
|
Daily measurements - for the whole duration of follow-up (2 months).
|
|
Indoor concentration levels of Particulate Matter 10 (PM 10) at residence
Time Frame: Daily measurements - for the whole duration of follow-up (2 months).
|
Indoor concentration levels of PM10 (micrograms per cubic meter of air) at participants' residences will be measured continuously indoors using commercial lightweight sensors (Alpha sense).
|
Daily measurements - for the whole duration of follow-up (2 months).
|
|
Number of daily steps
Time Frame: Daily measurements - for the whole duration of follow-up (2 months)
|
Number of daily steps will be measured throughout the day by a wearable device (wristband).
|
Daily measurements - for the whole duration of follow-up (2 months)
|
|
Daily heart rate
Time Frame: Daily measurements - for the whole duration of follow-up (2 months) .
|
Heart rate measurements taken throughout the day by a wearable device (wristband).
|
Daily measurements - for the whole duration of follow-up (2 months) .
|
|
Sleep-wake pattern
Time Frame: Daily measurements - for the whole duration of follow-up (2 months)
|
Sleep-wake pattern will be estimated based on measurements of movement and heart rate obtained from a wearable device (wristband)
|
Daily measurements - for the whole duration of follow-up (2 months)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Panayiotis Yiallouros, Professor, University of Cyprus
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 101156653.LL1.OW
- 101156653 (Other Grant/Funding Number: European Commission)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heat Strain
-
Northern Arizona UniversityRecruitingExercise | Control Condition | Heat StrainUnited States
-
Petros DinasCompleted
-
Beth Israel Deaconess Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Boston...RecruitingHealthy Volunteer Study | Kidney Dysfunction | Heat StrainUnited States
-
University of Texas Southwestern Medical CenterNational Institute on Aging (NIA); The American Society of EchocardiographyRecruitingHyperthermia | Aging | Heat Stress | Heat StrainUnited States
-
Harvard School of Public Health (HSPH)Fogarty International Center of the National Institute of HealthRecruitingHeat Stress | Heat Exposure | Heat Effect | Hot Weather; Adverse Effect | Heat Stroke, Heat Exhaustion | Heat StrainUnited States
-
University of OttawaCompletedPhysiological Stress | Heat StressCanada
-
University of OttawaCompletedHyperthermia | Aging | Heat Stress | Weather; Heat | Heat SyncopeCanada
-
University of OttawaCompletedPhysiological Stress | Heat StressCanada
-
Universidad Católica San Antonio de MurciaNot yet recruitingMuscle Strain | Electromyography | Trapezius Muscle Strain
-
Fundación Universidad Católica de Valencia San...CompletedSports Physical Therapy | Thermography | Strain of Gastrocnemius Muscle (Diagnosis) | Diathermy Plate BurnSpain
Clinical Trials on Heat intervention
-
Manchester Metropolitan UniversityBritish Heart FoundationNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Intermittent Claudication | Vascular Function | Cardiovascular HealthUnited Kingdom
-
Monash University MalaysiaMonash University; Heidelberg University; Ministry of Health, MalaysiaNot yet recruitingHeat; Weather | Heat Effect | Climate Change | Heat; ExcessMalaysia
-
University of CyprusUniversity of Catania; Azienda ospedaliera Garibaldi CataniaRecruitingSleep QualityCyprus, Italy
-
Sheba Medical CenterUnknownBody Temperature ChangesIsrael
-
Université de MontréalInstitut de Recherche Robert-Sauvé en Santé et en Sécurité du TravailUnknown
-
University of CyprusFUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA; PANCYPRIAN...RecruitingHypertension Arterial | 65 Years OlderSpain, Cyprus
-
Universidad Peruana Cayetano HerediaTulane University School of MedicineAvailableCutaneous Leishmaniasis
-
Tribhuvan University, NepalCompletedLabour Pain | Heat Therapy | Cold TherapyNepal
-
Robert Jones and Agnes Hunt Orthopaedic and District...Action Medical ResearchCompletedCerebral PalsyUnited Kingdom
-
Sheba Medical CenterCompletedHealthy | Heat StrokeIsrael